KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Current Assets (2016 - 2025)

Historic Current Assets for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to $4.0 billion.

  • Alnylam Pharmaceuticals' Current Assets rose 1780.36% to $4.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 billion, marking a year-over-year increase of 1780.36%. This contributed to the annual value of $3.3 billion for FY2024, which is 1048.0% up from last year.
  • Alnylam Pharmaceuticals' Current Assets amounted to $4.0 billion in Q3 2025, which was up 1780.36% from $3.6 billion recorded in Q2 2025.
  • Alnylam Pharmaceuticals' 5-year Current Assets high stood at $4.0 billion for Q3 2025, and its period low was $2.5 billion during Q1 2021.
  • Its 5-year average for Current Assets is $2.9 billion, with a median of $2.8 billion in 2021.
  • Its Current Assets has fluctuated over the past 5 years, first soared by 5586.35% in 2021, then tumbled by 930.31% in 2022.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Current Assets stood at $2.8 billion in 2021, then dropped by 4.14% to $2.7 billion in 2022, then grew by 10.79% to $3.0 billion in 2023, then grew by 10.48% to $3.3 billion in 2024, then increased by 19.95% to $4.0 billion in 2025.
  • Its Current Assets was $4.0 billion in Q3 2025, compared to $3.6 billion in Q2 2025 and $3.3 billion in Q1 2025.